<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674138</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19578</org_study_id>
    <nct_id>NCT03674138</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients</brief_title>
  <official_title>Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial to investigate the clinical impact of a&#xD;
      preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients.&#xD;
      Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of&#xD;
      therapy or clinical management alone. Scores on self-reported measures of depressive and&#xD;
      anxiety symptoms along with quality of life will be compared between cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">October 2, 2022</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be blinded to the genomic results for 12 weeks, with the 12 week time period starting at the time of antidepressant drug prescribing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depressive symptoms from baseline, as measured by the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline, week 12, month 12</time_frame>
    <description>The Hospital Anxiety and Depression scale can range from 0 to 42 (14 questions each on a 0-3 point scale).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anxious symptoms from baseline, as measured by the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline, week 12, month 12</time_frame>
    <description>The Hospital Anxiety and Depression scale can range from 0 to 42 (14 questions each on a 0-3 point scale).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by Functional Assessment of Cancer Therapy-General (FACT-G) Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life as measured by Functional Assessment of Cancer Therapy-General (FACT-G) Scale. FACT-G is a quality of life questionnaire with values ranging from 0 (not at all) to 4 (very much). The categories of measure are physical, social/family, emotional and functional well-being.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <condition>Depressive Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>DNA-guided choice of therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DNA-guided choice of antidepressant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical management</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DNA-guided choice of therapy</intervention_name>
    <description>Buccal swab for DNA genotyping to identify best antidepressant therapy</description>
    <arm_group_label>Clinical management</arm_group_label>
    <arm_group_label>DNA-guided choice of therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical management</intervention_name>
    <description>Clinical management to identify best antidepressant therapy</description>
    <arm_group_label>Clinical management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a cancer diagnosis&#xD;
&#xD;
          -  Be 18 years of age or older&#xD;
&#xD;
          -  Patients who rate depression or anxiety &gt; 5 based on a 10 point scale&#xD;
&#xD;
          -  Patients expected to live greater than 6 months&#xD;
&#xD;
          -  Serum bilirubin and creatinine &lt; 1.5x upper limit of normal&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Able to complete self-assessment questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not diagnosed with cancer&#xD;
&#xD;
          -  Antidepressant prescribing performed by a non-Moffitt psychiatrist after enrollment&#xD;
             onto the clinical trial&#xD;
&#xD;
          -  Known Pregnancy&#xD;
&#xD;
          -  History of liver or allogenic stem cell transplant&#xD;
&#xD;
          -  Patients with a known cognitive impairment (e.g., delirium, dementia, etc.) or&#xD;
             psychological impairment (e.g., schizophrenia, bipolar disease, etc.) other than&#xD;
             depressive and anxiety symptoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K Hicks, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

